

****PRESS RELEASE****For Immediate Release**

Category V Biotech, Inc. (c/k/a 4Cable TV International, Inc.) Announces:

Strategic Acquisition of FreddyCo, LLC and Miami FL Distribution, LLC

Strategic Partnership with RM Management Group

Cannabis Testing Innovation with GeneScape™ Platform to be deployed 1st Quarter 2025

Miami, FL – [September 29, 2024]

****Strategic Acquisition of FreddyCo, LLC and Miami FL Distribution, LLC****

Category V Biotech, Inc., currently known as 4Cable TV International, Inc., is thrilled to announce the acquisition of Freddyco, LLC and Miami FL Distribution, LLC. This acquisition marks an expansion of the company’s footprint in the rapidly growing hemp product market and strengthens its distribution capabilities nationwide. The combined companies are projected to generate approximately \$2.4 million in annual revenues.

Both Freddyco and Miami FL Distribution specialize in logistics and distribution of hemp-based products, contributing a monthly sales volume of approximately \$200,000. With the integration of these companies, Category V Biotech aims to streamline its operations, optimize supply chains, and reduce costs, thereby accelerating revenue growth.

“This acquisition represents a significant step forward for Category V Biotech,” said Michael Feldenkrais, CEO of Category V Biotech, Inc. “By acquiring these key distribution companies, we can substantially broaden our market reach, improve operational efficiencies, and meet the growing demand for hemp-based products more effectively. This move not only strengthens our position within the hemp industry but also supports our long-term growth objectives.”

Optimizing Operations and Market Position

The integration of Freddyco and Miami FL Distribution is expected to provide immediate operational benefits, particularly in supply chain optimization and cost reduction. By leveraging Category V’s existing supplier relationships, the company anticipates enhanced sourcing capabilities, improved product quality, competitive pricing, and a stronger foothold in the expanding hemp market.

To ensure maximum operational efficiency, Category V plans to implement best practices in logistics and inventory management, which will improve delivery times, reduce overhead costs, and enable the company to scale its operations to meet increasing consumer demand.

CATEGORY V is positioned for growth in the Hemp Industry

As the hemp industry continues its rapid expansion, driven by increasing consumer demand and the broader acceptance of hemp-based products, Category V Biotech is well-positioned to capitalize on this growth. The acquisition of Freddyco and Miami FL Distribution strengthens Category V’s ability to deliver high-quality hemp products to a growing customer base, positioning the company for sustained growth in the years to come.

The management teams of Freddyco and Miami FL Distribution will continue to operate under their established brands, ensuring continuity for customers and business partners during the

transition. Category V remains committed to maintaining the high standards of service and quality for which both companies are known while integrating operational best practices to drive further efficiencies.

****Strategic Partnership with RM Management Group****

The acquisition is further bolstered by Category V Biotech's new strategic partnership with RM Management Group, a key investor and advisor. RM Management Group will be instrumental in driving the company's expansion efforts and improving operational efficiencies. The partnership will play a central role in the successful integration of Freddyco and Miami FL Distribution, and the restructure and organization of Category V Biotech. RM Management will be applying innovative solutions to ensure the growth of the Company. Category V Biotech will now move its corporate headquarters to RM Management Group's address located at 746 North Drive, Melbourne, FL 32934 in order to work closely with RM Management Group on the future of the company.

"We are excited to partner with Category V Biotech on this acquisition," said Oliver Hatchett, spokesperson for RM Management Group. "Our shared vision for growth and innovation positions us to maximize the potential of these newly acquired distribution companies, driving both revenue growth and operational improvements."

****Cannabis Testing Innovation with GeneScape™ Platform expected to be deployed in the First Quarter of 2025****

In parallel with the acquisition, Category V Biotech is in deployment stages with two of the largest laboratories testing Medical Marijuana. In collaboration with Genetic Networks, Category V is offering groundbreaking cannabis product testing services: Medical Predictiveness. As part of compliance testing in the Cannabis space, all products entering the market must have a Certificate of Analysis specifying its contents before they hit the market. Category V Biotech, by way of the GeneScape™ platform has designed a product to be deployed on the Certificates of Analysis. GeneScape™ is designed to generate functional signatures from cannabis products, offering insights into potential medical conditions treatable by those products.

Corey Nislow, (PHD) is a cell biologist and geneticist who has worked in the fields of drug discovery and biotechnology. Corey (a Canada Research Tier in Translational Genomics) brings 30 years of experience in biotech and academia in running large scale scientific collaborations on early-stage drug discovery and pre-IND clinical translation. He will direct CATV platforms of assay development, medical predictions and personalized wellness.


GeneScape™ consists of five key activities:

1. Cannabis product preparation for screening;
2. Extraction of chemical information from lab tests;
3. Use of annotated product data to determine global bioactivity;
4. Screening and analysis of bioactive compounds; and
5. Delivery of a comprehensive genome-wide report.

The platform's ATLAS process (Activity, Targets, Liability, Applications, Stability) provides cannabis companies with a clear pathway to make medical claims, achieve regulatory approval,

and ensure compliance. This innovative platform opens the door for the development of novel cannabis-derived medicines.

For the first time, patients using cannabis will be able to choose products that directly address their medical conditions, thanks to our Medical Predictions, eliminating the guesswork of trying products that may not effectively treat their symptoms.



Disclaimers and Scientific Evidence

- This product is not intended to diagnose, treat, cure, or prevent any disease.
- Qualified Health Claims (QHCs): Supported by scientific evidence but not meeting the "significant scientific agreement" (SSA) standard.
- Substance-disease relationships: Will include qualifying language to ensure the current level of scientific support is accurately reflected.
- Peer-reviewed basis: All assays and interpretations are based on rigorous scientific evidence but have not been fully evaluated for human health benefits.

The acquisitions, together with the strategic management partnership, coupled with Category V Biotech's innovative advancements in cannabis testing to provide Medical Predictiveness, positions the company for continued growth and leadership in the evolving hemp and cannabis industries.

As Florida continues to move forward in cannabis reform, **we urge all Floridians to vote yes on Amendment 3** this November, which would allow adults 21 years and older to possess, purchase, or use marijuana products for personal consumption. This amendment supports the responsible use of cannabis and strengthens Florida's position in the growing market for hemp and cannabis-based products.

For more information, visit (<https://catvbt.com>) or contact info@catvbt.com.

Michael Feldenkrais
CEO

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties.

There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.